A vaccine for dengue fever may be available in 4 years, and experts have identified key issues needing to be addressed for regulatory review and licensure of such a vaccine (Mahoney R et al. PLoS Med. 2011;8:e1000418).
Investigators from the Dengue Vaccine Initiative Consortium hosted by the International Vaccine Institute, Seoul, carried out the study in collaboration with the World Health Organization and institutions from the United States.
The investigators emphasize that a vaccine effective against all 4 dengue-causing viruses is the best approach for disease control. Clinical trials should be carried out in different countries and in populations in which the disease is endemic. Plans are being developed to provide appropriate training and capacity for developing national regulatory agencies in endemic countries.
Friedrich MJ. Evaluating Dengue Vaccines. JAMA. 2011;305(15):1527. doi:10.1001/jama.2011.477